Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28630760 | 0.88 | HDAC3 (0.46) | HDAC3HRH4HTR3ARAB9AL3MBTL1 | |
| SCHEMBL24026553 | 0.88 | KCNJ1 (0.49) | HDAC3HRH4HTR3ARAB9AL3MBTL1 | |
| SCHEMBL64138 | 0.84 | SMO (0.47) | HDAC3HRH4HTR3ARAB9AL3MBTL1 | |
| SCHEMBL24315987 | 0.83 | PRKCQ (0.43) | HDAC3HRH4HTR3ARAB9AL3MBTL1 | |
| SCHEMBL24315986 | 0.79 | SMO (0.44) | HDAC3RAB9AL3MBTL1HDAC1HDAC2 | |
| SCHEMBL27858848 | 0.79 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2 | |
| SCHEMBL81828 | 0.76 | HTR3A (0.52) | HRH4HTR3ARAB9AL3MBTL1 | |
| SCHEMBL21776925 | 0.75 | RAB9A (0.59) | HDAC3HTR3ARAB9AL3MBTL1HDAC2 | |
| SCHEMBL24003412 | 0.74 | ADRA1A (0.48) | HDAC3HDAC1HDAC2ADRA1A | |
| SCHEMBL27767055 | 0.74 | AOC3 (0.43) | HDAC3HRH4HTR3ARAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4553076-A1 | COMPOUNDS AS TRK INHIBITORS AND/OR RET INHIBITORS AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | JAK1, JAK2, JAK3 | HDAC3 874/4885HRH4 768/4885HTR3A 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.